New combo therapy shows promise for rare liver disease
Disease control
Completed
This study tested whether adding the drug bezafibrate to another drug, obeticholic acid, helps people with primary biliary cholangitis (PBC), a chronic liver disease. 72 adults with PBC took one or both drugs for 12 weeks. The main goal was to see if the combination improved live…
Phase: PHASE2 • Sponsor: Intercept Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 05:51 UTC